Business Overview: Arcus Biosciences, Inc. (NYSE: RCUS)

---

Executive Summary

Arcus Biosciences, Inc. is a late clinical-stage biopharmaceutical company based in Hayward, California, developing differentiated small-molecule and antibody therapies for cancer and, increasingly, inflammatory and autoimmune diseases. Its lead oncology candidates are in Phase 3 registrational trials, while a pipeline of inflammation programs built on its internal discovery platform is advancing toward the clinic.

Arcus's commercial strategy is built around a deep partnership with Gilead Sciences, which holds licenses and development options across much of its oncology portfolio and has invested heavily in the company, including board representation.

---

1. Core Business Model & How They Work

[ Internal Small-Molecule / Antibody Discovery ] ➡️ [ Phase 1/2 Proof-of-Concept ] ➡️ [ Partner Licensing/Option Payments (Gilead, Taiho, WuXi) ] ➡️ [ Phase 3 Registrational Trials ] ➡️ [ Co-Promotion (US) / Royalties (ex-US) ]

Arcus develops its own drug candidates in-house, then monetizes them through a mix of milestone and option payments from partners (chiefly Gilead, plus Taiho Pharmaceutical in Asia and WuXi Biologics for anti-PD-1 manufacturing/rights), while retaining U.S. co-promotion rights on key assets. It owns no manufacturing facilities, relying entirely on third parties for drug substance and product.

---

2. Pipeline / Programs (in place of formal segments)

Arcus is a single clinical-stage business organized around two therapeutic pillars:

┌─────────────────────────────┐
│     Arcus Biosciences        │
└───────────────┬───────────────┘
                │
   ┌────────────┴─────────────┐
   ▼                           ▼
┌─────────────────────┐   ┌─────────────────────────┐
│   Oncology Pipeline   │   │  Inflammation Pipeline   │
│ (casdatifan, domva-   │   │ (MRGPRX2, TNF, CCR6,    │
│ nalimab, quemli-      │   │  CD89, CD40L programs)  │
│ clustat, zimberel-    │   │                          │
│ imab)                 │   │                          │
└─────────────────────┘   └─────────────────────────┘

Oncology is the current value driver: casdatifan (HIF-2α inhibitor) is in Phase 3 for renal cell carcinoma with a cited peak sales opportunity above $2–3 billion across two planned registrational studies; quemliclustat (CD73 inhibitor) completed Phase 3 pancreatic cancer enrollment in September 2025; domvanalimab (anti-TIGIT) saw its lead Phase 3 study discontinued for futility in December 2025, a significant setback; zimberelimab (anti-PD-1) is a combination-therapy backbone tested in over 2,600 patients.

Inflammation is the earlier-stage next wave: five preclinical/research programs (MRGPRX2, TNF, CCR6, CD89, CD40 ligand), with the first expected to enter the clinic in 2026, targeting conditions like chronic urticaria and competing conceptually with established drugs like Dupixent and Humira.

---

3. Product Portfolio

---

4. Competitive Landscape

In oncology, Arcus competes against large, well-capitalized players including AstraZeneca, Bristol-Myers Squibb, Merck, Roche/Genentech, Novartis, Pfizer, GSK, and Regeneron/Sanofi — several of which (e.g., Merck's belzutifan in HIF-2α, AstraZeneca's rilvegostomig in TIGIT) have overlapping or more advanced programs in the same mechanisms Arcus is pursuing. In inflammation/immunology, Arcus's future candidates would compete against entrenched blockbusters like Dupixent, Xolair, and Humira.

---

5. Strategic Strengths & Risks

Strengths

• Deep-pocketed partner in Gilead, which funds significant option and milestone payments ($150M per program option fee, $100M anniversary payments) and shares development costs on optioned programs.
• Broad, diversified pipeline spanning oncology and a newer inflammation pillar, reducing single-program dependency going forward.
• Extensive patent estate — over 850 pending/issued patents as of early 2026.

Risks

• Domvanalimab's Phase 3 futility failure (December 2025) removed a flagship anti-TIGIT program and raises questions about the mechanism's clinical value industry-wide.
• No approved products or product revenue, with cash runway dependent on continued Gilead milestone/option payments and, potentially, further dilutive financing.
• Crowded competitive fields in both HIF-2α (Merck's approved belzutifan) and PD-1 (many approved competitors), raising the bar for differentiation.
• Single-source manufacturing suppliers with no disclosed redundancy, a supply-chain risk for clinical and eventual commercial material.

---

6. Financial Overview

---

7. Summary Conclusion

Arcus Biosciences' moat rests on a broad, well-protected oncology and inflammation pipeline and an unusually deep-pocketed commercial partnership with Gilead that both funds its R&D and validates its science. The December 2025 futility failure of its anti-TIGIT program domvanalimab is a real setback that narrows the near-term path to a first approval, putting more weight on casdatifan's Phase 3 renal cell carcinoma data and the earlier-stage inflammation pipeline to prove out the platform over the next several years.